Metronidazole for COVID-19: real-time analysis

Download Image

Post

c19early.org

Metronidazole for COVID-19

1 study with 44 patients

Serious outcome risk

Metronidazole

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Metronidazole studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−20%

Hospitalization (1)25%

RCTs (1)−20%

Late (1)−20%

00.511.5+

← Metronidazole
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Sep 30 2021	Kazempour et al., Iranian Journal of Pharmaceutical Research, doi:10.22037/ijpr.2021.114567.14917	Anti-inflammatory Effect of Metronidazole in Hospitalized Patients with Pneumonia due to COVID-19
Sep 30 2021	20% higher ICU admission (p=1), 25% shorter hospitalization (p=0.9), and 43% higher need for oxygen therapy (p=0.8). RCT 44 hospitalized patients with COVID-19 pneumonia showing no significant differences for oxygen saturation, length of hospital stay, or mortality with metronidazole treatment. The metronidazole group had significantly lower ESR levels ..